NASDAQ:LBRX • US50180M1080
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LB PHARMACEUTICALS INC (LBRX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-11 | Stifel | Maintains | Buy -> Buy |
| 2025-10-06 | Leerink Partners | Initiate | Outperform |
| 2025-10-06 | Stifel | Initiate | Buy |
| 2025-10-06 | Piper Sandler | Initiate | Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | |||
| EBITDA YoY % growth | -11.372M | -64.739M -469.28% | N/A | N/A | N/A | |
| EBIT YoY % growth | -11.376M | -64.83M -469.88% | N/A 55.75% | N/A -292.22% | N/A -32.55% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A -11.68% | N/A -0.43% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.46 | -0.59 | -0.90 | -1.22 -163.74% | -1.44 -215.08% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -12.12M -118.82% | -13.673M | -21.884M -93.87% | -31.294M -496.52% | -38.504M -217.68% |
All data in USD
10 analysts have analysed LBRX and the average price target is 43.35 USD. This implies a price increase of 77.66% is expected in the next year compared to the current price of 24.4.
The consensus EPS estimate for the next earnings of LB PHARMACEUTICALS INC (LBRX) is -0.46 USD and the consensus revenue estimate is 0 USD.